Purification of biological substances

• US 20020170859A1
• Filed: 03/27/2002
• Published: 11/21/2002
• Est. Priority Date: 02/22/1999
• Status: Active Grant

• Current Assignee: Smartflow Technologies Inc.
• Original Assignee: Henry B. Kopf
• Inventors: Kopf, Henry B.
• Granted Patent: US 6,569,340 B2
• Time in Patent Office: Days
• US Class Current: 210/635
• CPC Class Codes: B01D 15/1871 placed in series
• CPC Class Codes: B01D 15/361 Ion-exchange
• CPC Class Codes: B01D 15/3804 Affinity chromatography
• CPC Class Codes: C07K 1/18 Ion-exchange chromatography
• CPC Class Codes: C07K 1/22 Affinity chromatography or related techniques based upon selective absorption processes
• CPC Class Codes: C07K 1/34 by filtration, ultrafiltration or reverse osmosis
• CPC Class Codes: C07K 1/36 by a combination of two or more processes of different types
• CPC Class Codes: C12M 47/04 Cell isolation or sorting purging biological preparations of unwanted cells C12N5/0081, determining the presence or kind of microorganism C12Q1/04
• CPC Class Codes: C12M 47/12 Purification C12M47/04 takes precedence

Abstract

A process and apparatus for purifying one or more target substances from a source liquid, employing one or more cross-flow filter elements, and one or more types of chromatography resins, in combination, to provide purification with advantageous yield, product purity, and cost- and time-efficiency.

Claims

1. A method of manufacturing universal plasma from blood comprising serological Group A and/or Group B antibodies, said method comprising contacting blood comprising serological Group A and/or Group B antibodies with a chromatography resin comprising corresponding Group A and/or Group B antigen, and recovering an antibodies-depleted blood product as the universal plasma.

2. The method of claim 1, wherein the chromatography resin comprises microbeads.

3. The method of claim 1, further comprising inactivating any bioactive contaminants in the plasma during said method.

4. The method of claim 2, wherein the microbeads are formed of cellulose.

5. The method of claim 1, wherein said step of recovering the antibodies-depleted blood product comprises filtration separation of said chromatography resin from the blood subsequent to said blood contacting step.

6. The method of claim 5, wherein said filtration separation comprises cross-flow filtration.

7. The method of claim 3, wherein the bioactive contaminants comprise at least one contaminant selected from the group consisting of viruses, bacteria, parasites, immunoantigens and antibodies.

8. The method of claim 3, wherein the bioactive contaminants comprise at least one virus species.

9. The method of claim 8, wherein said at least one virus species is selected from the group consisting of HIV, hepatitis virus, rabies virus, Epstein-Barr virus, measles virus, mumps virus, chickenpox virus and Parvovirus.

10. The method of claim 8, wherein said at least one virus species includes HIV.

11. The method of claim 1, further comprising removing one or more contaminants from the blood, wherein the chromatography resin includes ligand(s) having binding affinity for said one or more contaminants.

12. The method of claim 11, wherein the one or more contaminants comprise a contaminant selected from the group consisting of viruses, bacteria, parasites, immunoantigens and antibodies.

13. The method of claim 11, wherein the one or more contaminants comprise at least one virus species.

14. The method of claim 13, wherein the at least one virus species is selected from the group consisting of HIV, hepatitis virus, rabies virus, Epstein-Barr virus, measles virus, mumps virus, chickenpox virus and Parvovirus.

15. The method of claim 14, wherein the at least one virus species comprises HIV.